Alzheimer's Research

1.Qureshi, A. I. & Caplan, L. R. Intracranial atherosclerosis. Lancet 383, 984–998 (2014).2.Roher, A. E. et al. Intracranial atherosclerosis as a contributing factor to Alzheimer’s disease dementia. Alzheimer’s Dement. 7, 436–444 (2011).3.Zlokovic, B. V....

Mouse strainsAll mouse work was approved by the Committee for Animal Care of the Division of Comparative Medicine at Massachusetts Institute of Technology. Hdac1f/f mice were gifted from E.N. Olson23. Hdac1f/f mice were bred...

1.Warrington, E. K. The selective impairment of semantic memory. Q. J. Exp. Psychol. 27, 635 (1975).2.Snowden, J. S., Goulding, P. J. & Neary, D. Semantic dementia: a form of circumscribed cerebral atrophy. Behav. Neurol....

1.World Health Organization. Dementia. WHO http://www.who.int/en/news-room/fact-sheets/detail/dementia. (Accessed 18 March 2020).2.Hachinski, V. et al. Alzheimers Dement. 15, 961–984 (2019).3.Iadecola, C. & Gottesman, R. F. Circ. Res. 123, 406–408 (2018).4.Iadecola, C. et al. J. Am. Coll....

UC San Francisco is the only JCAHO Comprehensive Stroke Center in San Francisco. What does this mean? According to Steven Hetts, MD, chief of Interventional Neuroradiology at the UCSF Mission...

1.Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO molecular medicine 8, 595–608 (2016).2.Association, A. s. 2019 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia 15, 321–387...

The primary objective of the open-label extension was to evaluate the long-term safety and tolerability of a transdermal rivastigmine patch up to 1 year, as a novel approach to treatment in Alzheimer disease. This...

Animal housing and handlingAPPPS1-21 mice in a C57BL6Cj background were obtained from M. Jucker (University of Tubingen, Tubingen, Germany) and were housed in the animal research center facility at the University of Chicago. Mice...

Advancements in clinical therapies have identified the need for biomarkers of early Alzheimer disease that distinguish the earliest stages of pathology and target those patients who are likely to gain the most benefit. The...

1.Au, R., Piers, R. J. & Lancashire, L. Back to the future: Alzheimer’s disease heterogeneity revisited. Alzheimers Dement (Amst) 1, 368–370 (2015).2.Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele...